0001701478-26-000037 | 10-Q | XBRL Viewer

Print Document

Commitments and Contingencies - Schedule of Future Minimum Payments Under Non-cancelable Operating Leases (Details)	Jun. 30, 2026 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2026	$ 204,806
2027	194,145
2028	20,864
Thereafter	0
Total future undiscounted lease payments	419,815
Less interest	(11,248)
Present value of minimum lease payments	$ 408,567

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2026
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Accounting The financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). Certain amounts in the condensed financial statements and associated notes may not add up due to rounding. Unaudited Interim Financial Information The unaudited interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information, within the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis consistent with the audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented and of the financial condition as of the date of the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial statements related to the six months are unaudited. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2025, and notes thereto that are included in the Company’s Annual Report on Form 10-K as filed with the SEC on February 27, 2026. Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet. While management believes the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. The most significant estimates in the Company's financial statements relate to accruals for research and development expenses, valuation of warrants and valuation of equity awards, and the recoverability of our deferred patent costs. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Concentration of Credit Risks and other Risks and Uncertainties Financial instruments, which potentially subject the Company to significant concentrations of risk, consist principally of cash and cash equivalents. The Company’s cash is deposited with a federally insured U.S. financial institution. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. The Company is dependent on contract research organizations ("CRO") to conduct, and manage our on-going clinical trials, and contract manufacturing organizations (“CMO”) to supply products for research and development of its product candidates, including preclinical and clinical studies, and for commercialization of its product candidates, if approved. The Company’s development programs could be adversely affected by any significant interruption in either the CRO's or the CMO’s operations or by a significant interruption in the supply of active pharmaceutical ingredients and other components. Products developed by the Company require approval from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s product candidates will receive the necessary approvals. If the Company is denied approvals, approvals are delayed, or the Company is unable to maintain approvals received, such events could have a materially adverse impact on the Company. The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements. Segment Information The Company operates and manages its business as one operating segment, which is to discover and develop novel therapeutics to create a new paradigm for treating skin diseases and leverage our existing technologies to develop cosmetic ingredients for consumer-oriented products. The Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), reviews financial information on an aggregate basis, along with cash balances for purposes of allocating resources and evaluating performance. For additional segment disclosures, see Note 13. Cash and Cash Equivalents For purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid investments with original maturities of three months or less to be cash equivalents. Deferred Offering and Deferred Issuance Costs The Company capitalizes deferred offering costs, which primarily consists of direct, incremental legal, professional, accounting, and other third-party fees relating to the Company’s public offering initiatives associated with the filing of an S-1 Registration Statement. Once the Company completes the public offering, the Company records these amounts against the gross proceeds of these public offerings within the statements of stockholders’ equity. In July 2024, the Company also filed a Form S-3 Registration Statement and recorded deferred issuance costs as a long-term asset. In September 2025, the Company wrote off the remaining deferred issuance costs of $35,435 as it was uncertain the Company would be able to issue additional shares against the Form S-3 Registration Statement. The write-off resulted in a reduction to additional paid-in capital. Leases The Company elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance, the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months. Leases are classified as either operating or financing leases based on the economic substance of the agreement. The Company has 3 operating leases for buildings and recorded an initial ROU assets and lease liabilities totaling $1,418,502. The basis, terms and conditions of the leases are determined by the individual agreements. The Company’s option to extend certain leases ranges from 36 – 52 months. All options to extend have been included in the calculation of the ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions. At June 30, 2026, the Company had operating right-of-use assets with a net value of $406,455 and current and long-term operating lease liabilities of $357,569 and $50,998, respectively. In 2023, the Company entered into a lease for the use of certain equipment that is classified as a finance lease. The finance lease has a term of 36 months. At June 30, 2026, the Company had financing right-of-use assets with a net value of $1,301 and current and long-term financing lease liabilities of $1,486 and $—, respectively. Deferred Patent Costs Deferred patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval. These deferred costs will be reclassed to intangible assets and begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent is not issued, the costs associated with the patent will be expensed in the year the patent was rejected. Deferred patent costs are reviewed for impairment at each reporting period. The costs associated with any impairment are expensed in the period the deferred patent costs are determined to be impaired. In connection with its review of the first quarter financial statements, the Company recorded impairment expenses of $623,532 during the three months ended March 31, 2026 related to our pending international patent applications, which were determined to be impaired due to a significant increase in the time of such patent approvals, decreases in the granting of such approvals, and the Company's strategic focus on the domestic patents. The Company did not record any impairment expenses during the second quarter of 2026. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, Research and Development. Accordingly, research and development costs are expensed as incurred. Research and development costs consist of costs related to labor, materials and supplies, as well as fees paid to consultants, external research fees. Research and development costs incurred were $1,351,529 and $2,912,094 for the three and six months ended June 30, 2026, respectively. Research and development costs incurred were $1,401,839 and $2,651,939 for the three and six months ended June 30, 2025, respectively. At June 30, 2026 and December 31, 2025, the Company had state tax credit receivables of $103,601 for pending refunds related to the selling of research and development tax credits back to the State of Connecticut. At June 30, 2026 and December 31, 2025, the Company had recorded $26,295 and $27,269, respectively, for pending refunds related to Canadian Scientific Research and Experimental Development (SRED) credits. At June 30, 2026 and December 31, 2025, the Company had recorded $13,925 and $9,513, respectively, related to refunds of Canadian Goods and Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in research and development on the statements of operations. Recent and Adopted Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)." Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. The standard provides guidance to expand disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, on a retrospective or prospective basis, with early adoption permitted. We are currently evaluating this ASU to determine its impact on our disclosures. In July 2025, the FASB issued ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”, which introduces a practical expedient that allows entities to assume that current conditions at the balance sheet date remain unchanged for the remaining life of the asset when developing reasonable and supportable forecasts. This eliminates the need to incorporate macroeconomic forecasts for short term receivables. The ASU is effective for fiscal years beginning after December 15, 2025. The Company adopted ASU 2025-05 on January 1, 2026, on a prospective basis, which did not have a significant impact on the financial statements and related disclosures.

Organization and Nature of Operations	6 Months Ended
Organization and Nature of Operations	Jun. 30, 2026
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations Azitra, Inc. (the "Company," "Azitra," "We," "us," and "our".) was founded on January 2, 2014. We are a synthetic biology company focused on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products by screening and genetically engineering microbes of the skin. The mission is to discover and develop novel therapeutics to create a new paradigm for treating skin disease. The Company’s discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides and small molecules for precision treatment of dermatology diseases. Azitra also leverages these technologies to develop cosmetic ingredients for consumer-oriented products as well as recombinant proteins and peptides for research. On May 17, 2023, the Company changed its name to from “Azitra Inc” to “Azitra, Inc.” In addition to our corporate headquarters located in Branford, Connecticut, the Company maintains a location in Montreal, Canada for certain research activities. The Company also opened a manufacturing and laboratory space in Groton, Connecticut during 2021. Stock Splits, Change in Par Value, Increase in Shares Authorized, Initial and Follow-on Public Offerings, and Equity Line of Credit Issuances In June 2023, the Company completed its initial public offering (IPO) in which it issued and sold 7,508 shares of its common stock at a price to the public of $999.00 per share. The shares began trading on the NYSE American on June 16, 2023 under the symbol “AZTR”. The net proceeds received by the Company from the IPO were $6.0 million, after deducting underwriting discounts, commissions and other offering expenses. Immediately prior to the effectiveness of the Company’s registration statement, the Company effected a 7.1-for-1 forward stock split (the "Forward Stock Split") of its issued and outstanding shares of common stock. On May 17, 2023, the Company changed the par value of its capital stock from $0.01 to $0.0001. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been adjusted retroactively, unless otherwise noted, to reflect the effect of the Forward Stock Split. Refer to Note 6 for additional details relating to the Forward Stock Split. In February 2024, the Company completed a follow-on public offering (the "February 2024 Offering") in which it issued and sold 83,404 shares of its common stock at a price to the public of $59.94 per share. The net proceeds received by the Company from the follow-on public offering were $4.3 million, after deducting underwriting discounts, commissions and other offering expenses. For further information regarding the February 2024 Offering and related warrant issuance, refer to Notes 6 and 7 respectively. On July 1, 2024, the Company effected a 30-for-1 reverse stock split of its issued and outstanding shares of common stock (the "2024 Reverse Stock Split") and began trading on a split-adjusted basis the same day. There was no change in par value. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the effect of the 2024 Reverse Stock Split. Refer to Note 6 for additional details relating to the Reverse Stock Split. In July 2024, the Company completed a follow-on public offering (the "July 2024 Offering") in which it issued and sold 1,000,750 shares of its common stock at a price of $9.99 per share and Class A Warrants exercisable for an aggregate 2,001,502 shares of common stock. The net proceeds received by the Company from the follow-on public offering were $9.1 million, after deducting placement agent's fees and other offering expenses. For further information regarding the July 2024 Offering and related warrant issuance, refer to Notes 6 and 7 respectively. In January 2025, the Company completed a follow-on offering (the "January 2025 Offering") in which it issued and sold 729,381 shares of its common stock at a price of $2.00 per share. The net proceeds received by the Company from the January 2025 offering were $1.2 million, after deducting placement agent's fees and other offering expenses. The shares were offered by the Company pursuant to a shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and a final prospectus supplement dated January 15, 2025. For further information regarding the January 2025 Offering, refer to Notes 6 and 7 respectively. In February 2025, the Company completed a follow-on offering (the "February 2025 Offering") in which it issued 374,696 shares of its common stock at a public offering price of $1.85 per share and warrants to purchase up to 337,232 shares of common stock at an exercise price of $3.60. The net proceeds received by the Company from the February 2025 offering were $560,976 after deducting placement agent's fees and other offering expenses. The shares were offered by the Company pursuant to a shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and a final prospectus supplement dated February 6, 2025. For further information regarding the February 2025 Offering and related warrant issuance, refer to Notes 6 and 7, respectively. On April 24, 2025, the Company entered into an Equity Line of Credit ("ELOC"), as amended, with Alumni Capital LP ("Alumni Capital"), whereby the Company has the right, but not the obligation, to sell to Alumni Capital, and Alumni Capital is obligated to purchase, up to an aggregate of $20 million of shares of the Company's common stock in a series of purchases. Upon each purchase, Alumni Capital will receive warrants to purchase shares of the Company's common stock equal to 10% of the number of shares purchased in the related purchase. Under the terms of the ELOC, the Company has issued an aggregate of 9,255,823 shares of common stock and issued 925,579 warrants. The aggregate gross proceeds received by the Company under the ELOC are $6.2 million. As of August 11, 2026, approximately $13.8 million is available under the ELOC for future share issuances. For further information regarding the ELOC, refer to Notes 6 and 7 respectively. In July 2025, the Company filed a certificate of amendment to the Second Amended and Restated Certificate of Incorporation increasing the number of authorized shares of common stock from 100,000,000 to 200,000,000. In June 2026, the Company filed a certificate of amendment to the Second Amended and Restated Certificate of Incorporation increasing the number of authorized shares of common stock from 200,000,000 to 750,000,000. On August 21, 2025, the Company effected a 6.66-for-1 reverse stock split of its issued and outstanding shares of common stock (the "2025 Reverse Stock Split") and began trading on a split-adjusted basis the same day. There was no change in par value. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the effect of the 2025 Reverse Stock Split. Refer to Note 6 for additional details relating to the 2024 Reverse Stock Split, and the 2025 Reverse Stock Split (together, the "Reverse Stock Splits"). On November 24, 2025, the Company entered into a securities purchase agreement (the “November Purchase Agreement”) with Alumni Capital pursuant to which the Company agreed to issue and sell to Alumni Capital in a private placement offering (the " November PIPE Offering") priced at a premium to market in accordance with NYSE rules an aggregate of 535,759 shares of common stock of the Company, (ii) pre-funded warrants (the “November Pre-Funded Warrants”) to purchase up to an aggregate of 4,151,741 shares of Common Stock (the “November Pre-Funded Warrants Shares”) at an exercise price of $0.0001 per November Pre-Funded Warrant, and (iii) common stock purchase warrants (the “November Common Warrants” together with the November Pre-Funded Warrants, the “November Warrants”) to purchase up to an aggregate of 4,687,500 shares of Common Stock (the “November Common Warrant Shares” together with the November Pre-Funded Warrant Shares, the “November Warrant Shares”) at an exercise price of $0.32 per November Common Warrant. The offering price was $0.32 per share of Common Stock or November Pre-Funded Warrant and accompanying November Common Warrant (the “Offering Price”). The November Pre-Funded Warrants are immediately exercisable and do not expire until exercised in full. The November Common Warrants were exercisable upon shareholder approval and will expire on the five-year anniversary of shareholder approval. For further information regarding the PIPE Offering, refer to Notes 6 and 7 respectively. During the six months ended June 30, 2026, all November Pre-Funded Warrants have been exercised by Alumni Capital. On March 18, 2026, the Company entered into a securities purchase agreement (the "Series A Purchase Agreement") in which it issued and sold 10,485 shares of its Series A Preferred Stock (the "Series A Offering") at a price of $1,000 per share, which are convertible into 85,223,126 shares of common stock, Series B Warrants exercisable for an aggregate 85,223,126 shares of common stock, and Series C Warrants exercisable for an aggregate 85,223,126 shares of common stock. The net proceeds received by the Company from the Series A Offering were approximately $10.4 million, after deducting offering expenses. For further information related to the Series A Offering and related warrant issuances, refer to Notes 6 and 7 respectively. On June 16, 2026, pursuant to the terms of the Series A Purchase Agreement, the 10,485 shares of Series A Preferred Stock converted to 36,715,229 shares of common stock and 48,507,897 pre-funded warrants. Other Events On October 1, 2025, the Company received a deficiency letter (the “Deficiency Letter”) from the NYSE American LLC ("NYSE American") indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide. Section 1003(a)(ii) of the NYSE American Company Guide requires a listed company’s stockholders’ equity be at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Deficiency Letter noted that the Company reported stockholders’ equity of $2.2 million as of June 30, 2025, and losses from continuing operations and/or net losses in three of its four most recent fiscal years ended December 31, 2024. In order to maintain the Company’s listing on the NYSE American, the NYSE American requested that the Company submit a plan of compliance (the “Plan”) by October 31, 2025 addressing how the Company intends to regain compliance with Section 1003(a)(ii) of the NYSE American Company Guide by April 1, 2027. The Company’s management submitted the Plan to the NYSE American by the October 31, 2025 deadline which was accepted by the NYSE American on December 16, 2025. If the Company does not make progress consistent with the Plan during the plan period or if the Company is not in compliance with the listing standards by April 1, 2027, then the Company will be subject to delisting procedures as set forth in the NYSE American Company Guide. On March 13, 2026, the Company received an additional letter (the “March 2026 Letter”) from the NYSE American indicating that the Company is also not in compliance with the continued listing standard set forth in Section 1003(a)(iii) of the NYSE American Company Guide, which requires stockholders’ equity of at least $6.0 million if a listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The March 2026 Letter noted that the Company reported stockholders’ equity of $3.8 million as of December 31, 2025 and losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025. The Company is seeking to regain compliance with Section 1003(a)(iii), in addition to Section 1003(a)(ii), of the NYSE American Company Guide by the April 1, 2027 plan period deadline pursuant to the Plan. During the plan period, the Company must provide quarterly updates to the NYSE American staff concurrent with its periodic filings, and if the Company does not make progress consistent with the Plan or does not regain compliance by the plan period deadline, the NYSE American may initiate delisting proceedings. As of June 30, 2026, the Company reported total stockholders’ equity of approximately $7.3 million, which exceeds the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. Any determination that the Company has regained compliance with the applicable continued listing standards will be made by the NYSE American, and the Company remains subject to the Plan and the NYSE American’s periodic review during the plan period. There can be no assurance that the Company will regain, or thereafter maintain, compliance with all applicable NYSE American continued listing standards. The Company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE American’s requirements. There can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing standards within the required time frame. Going Concern Matters The unaudited condensed financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the foreseeable future, and which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, management has identified the following conditions and events that created an uncertainty about the ability of the Company to continue as a going concern. As of and for the six months ended June 30, 2026, the Company has an accumulated deficit of approximately $75.8 million, a loss from operations of approximately $7.4 million, used approximately $5.8 million to fund operations and had approximately $5.9 million of working capital. The Company will require a significant amount of additional funds to complete the development of its product and to fund additional losses which the Company expects to incur over the next few years. The Company is still in its pre-commercialization phase and therefore does not yet have product revenue. Management plans to continue to raise funds through equity and/or debt financing to fund operating and working capital needs; however, there can be no assurance that the Company will be successful in securing additional financing, if needed, to meet its operating needs. These conditions and events create substantial doubt about the ability of the Company to continue as a going concern for twelve months from the date that the financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Commitments and Contingencies - Schedule of Future Minimum Payments Under Finance Leases (Details)	Jun. 30, 2026 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2026	$ 1,486
Total future undiscounted lease payments	1,486
Less interest	0
Present value of minimum lease payments	$ 1,486

Warrants

6 Months Ended

Jun. 30, 2026

Warrants [Abstract]

Warrants

The Company issued warrants to purchase 238 shares of common stock in 2018 in conjunction with convertible debt financing that have a redemption provision providing the holder the right to have the Company redeem all or any portion of the warrant (or shares it has converted into) at a purchase price equal to the fair market value of the shares as determined by the board of directors or an independent appraiser. As a result of this redemption provision, the warrants have been classified as a liability in the financial statements based on ASC 480. These warrants have an exercise price of $95.90 per share and a term of 10 years. The warrants are adjusted to their current fair value each reporting period. The fair value was $— at June 30, 2026 and December 31, 2025, respectively.

The Company issued 300 warrants to its underwriters as part of our initial public offering in fiscal 2023. In fiscal 2024, the Company issued an additional 3,336 warrants in February, and 40,030 warrants in July to its underwriters as part of our February, and July Offerings. The underwriter warrants have a term of 5 years.

In connection with the February 2024 Offering, the Company also issued warrants to designees to the February 2024 Placement Agent exercisable for an aggregate of 3,336 shares of Common Stock at an exercise price of $75.92 per share (125% of the $60.74 public offering price) and which expire on February 13, 2029. The warrants were evaluated in accordance with ASC 718 and recorded within stockholders' equity.

The Company issued 2,001,502 Class A Warrants to investors who participated in the Company's July 2024 Offering. The Class A Warrants had an initial exercise price of $9.99 per share of Common Stock; however, on August 24, 2024 the exercise price was reset to $4.69. See Note 6. The number of shares of Common Stock issuable upon exercise of the Class A Warrants were not proportionately adjusted in connection with the reset of the exercise price.

The Class A Warrants are exercisable upon issuance and expire five years from the date of issuance. The Class A Warrants contain ownership limitations pursuant to which a holder does not have the right to exercise any portion of their warrants if it would result in

the holder (together with its affiliates) beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of the Company’s outstanding Common Stock. The Class A Warrants are issued pursuant to a Warrant Agent Agreement dated July 25, 2024 (“Warrant Agent Agreement”) between the Company and VStock Transfer LLC, as warrant agent. In August 2024, 150 warrants were exercised for proceeds of $704.

In connection with the July 2024 Offering, the Company evaluated the Class A Warrants and determined they met the criteria for liability classification as they met the criteria in ASC 815 - Derivatives and Hedging due to the reset provision. The Class A Warrants had an initial fair value of $12.1 million. The gross proceeds of approximately $10.0 million from the July 2024 follow-on public offering was allocated to the Class A Warrants resulting in a loss on issuance of common stock of approximately $2.1 million recorded in Other income (expenses). Upon the reset of the Class A Warrant exercise price, the Class A Warrants no longer met the criteria for liability classification pursuant to ASC 815; at which time the Company recorded a gain in Other income (expenses) - Change in fair value of Class A warrants of $4.0 million, and reclassified $1.9 million to equity representing the difference between the change in the fair value, and the loss upon issuance of our common stock.

The Class A Warrants were valued utilizing a probability weighted scenario method with a Monte Carlo simulation model and Black-Scholes Model. The significant assumptions in the Monte Carlo simulation model include a stay public assumption of 90%, and a fundamental transaction assumption of 10%. The significant assumptions utilized in estimating the fair value of the Class A Warrants at issuance include (i) a per share price of common stock range of $1.14 - $1.40; (ii) a dividend yield of 0%; (iii) a risk-free rate range of 4.13% - 4.14%; (iv) expected volatility of 119%; (v) projected stock price and volume weighted average price as of the Reset Date of $1.14; (vi) a strike price range of $1.40 - $1.50; and (vii) expected term of 4.92 years.

In connection with the July 2024 Offering, the Company also issued warrants to designees of the July 2024 Placement Agent exercisable for an aggregate of 40,030 shares of common stock. The warrants have substantially the same terms as the Class A Warrants, except that the July 2024 Placement Agent warrants have an exercise price equal to $12.49 per share (125% of the $9.99 public offering price), have an initial exercise date of January 23, 2025 and expire on July 23, 2029. The 2024 Placement Agent warrants were evaluated in accordance with ASC 718 and recorded within stockholders' equity.

In connection with the January 2025 Offering, as consideration for Maxim Group LLC serving as the Placement Agent of the January 2025 Offering, the Company also issued warrants to designees of the Placement Agent exercisable for an aggregate of 29,175 shares of common stock, which represent 4.0% of the aggregate number of shares of common stock sold in the offering, at an exercise price per share equal to 125% of the public offering price of $2.50. The warrants are exercisable six months from the date of issuance and expire five years from the commencement of the sales in this offering. The warrants may be exercisable via cashless exercise in certain circumstances. The warrants were evaluated in accordance with ASC 718 and recorded within stockholders' equity.

In connection with the February 2025 Offering, the Company issued warrants to purchase up to 337,232 shares of common stock at an exercise price of $3.60. The warrants are exercisable on the six-month and one day anniversary of their issuance, and their exercise price was calculated as the greater of the (i) book value of the common stock or (ii) market value of the common stock as determined by the NYSE American Rules. The warrants were evaluated in accordance with ASC 718 and recorded within stockholders' equity.

In connection with shares issued to Alumni Capital under the terms of the ELOC, as amended, Alumni Capital will receive warrants to purchase such number of shares of the Company’s common stock equal to 10% of the number of shares purchased in the related purchase. The Exercise Price shall equal 130% of the price per share paid upon closing. The exercise of the warrant will be subject to stockholder approval and expire five years after issuance. The warrants may be exercised via cashless exercise if there is no effective registration statement, or current prospectus available for, the resale of the warrant shares. The Company has issued an aggregate 925,579 warrants as of June 30, 2026.

In connection with the November PIPE Offering, the Company issued November Pre-Funded Warrants to purchase up to 4,151,741 shares of common stock at an exercise price of $0.0001, and November Common Warrants to purchase up to an aggregate of 4,687,500 shares of common stock at an exercise price of $0.32 per November Common Warrant. The November Pre-Funded Warrants are immediately exercisable and do not expire until exercised in full. The November Common Warrants are exercisable upon shareholder approval and will expire on the five-year anniversary of shareholder approval. For the three and six months ended June 30, 2026, all November Pre-Funded Warrants have been exercised by Alumni Capital.

In connection with the November PIPE Offering, as consideration for Maxim Group LLC serving as the PIPE Placement Agent, the Company also issued warrants to designees of the PIPE Placement Agent exercisable for an aggregate of 187,500 shares of common stock, which represent 4.0% of the aggregate number of shares of common stock sold in the offering, at an exercise price per share equal to 125% of the public offering price of $0.32. The warrants are exercisable six months from the date of issuance and expire five years from the commencement of the sales in this offering. The warrants may be exercisable via cashless exercise in certain circumstances. The warrants were evaluated in accordance with ASC 718 and recorded within stockholders' equity.

In connection with the Series A Preferred Offering, the Company issued 48,507,897 pre-funded warrants due to beneficial ownership limitations and are immediately exercisable until fully exercised, and Series B and Series C Warrants to purchase up to 85,223,126 and 85,223,126 shares of common stock with an exercise price of $0.123 respectively. The Series B Warrants are currently exercisable and will terminate 18 months following the requisite shareholder approval which occurred in June 2026. The Series C Warrants became exercisable upon the requisite shareholder approval and the certificate of amendment filing as defined in the Series A Purchase Agreement which occurred in June 2026, and will terminate 30 calendar days after the date the Company publicly announces data from its cosmetic filaggrin study in humans.If the closing sale price of the common stock is below the exercise price of the Series C Warrants on the termination date, the exercise price will automatically reset to the closing sale price on such date (subject to a floor equal to 50% of the original exercise price) and the termination date will be extended by an additional 30 calendar days. The warrants were evaluated in accordance with ASC 718 and recorded within stockholders' equity.

The following table summarizes information about warrants outstanding at June 30, 2026:


			Warrants Outstanding				Warrants Exercisable
Year Granted	Exercise Price		Number of Warrants at 06/30/2026	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number of Warrants at 06/30/2026	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price

2018	$	95.90	238	1.8 years	$	95.90	238	1.8 years	$	95.90
2023	$	1,248.75	300	2.0 years	$	1,248.75	300	2.0 years	$	1,248.75
2024	$	75.92	3,336	2.7 years	$	75.92	3,336	2.7 years	$	75.92
2024	$	4.69	2,001,349	3.1 years	$	4.69	2,001,349	3.1 years	$	4.69
2024	$	12.49	40,030	3.1 years	$	12.49	40,030	3.1 years	$	12.49
2025	$	2.50	29,175	3.6 years	$	2.50	29,175	3.6 years	$	2.50
2025	$	3.60	337,232	4.1 years	$	3.60	337,232	4.1 years	$	3.60
2025	$	2.33	11,216	3.9 years	$	2.33	11,216	3.9 years	$	2.33
2025	$	2.17	11,261	3.9 years	$	2.17	11,261	3.9 years	$	2.17
2025	$	2.12	11,261	3.9 years	$	2.12	11,261	3.9 years	$	2.12
2025	$	2.32	11,261	4.0 years	$	2.32	11,261	4.0 years	$	2.32
2025	$	1.86	13,513	4.0 years	$	1.86	13,513	4.0 years	$	1.86
2025	$	1.78	13,513	4.0 years	$	1.78	13,513	4.0 years	$	1.78
2025	$	1.75	13,513	4.1 years	$	1.75	13,513	4.1 years	$	1.75
2025	$	1.70	13,513	4.1 years	$	1.70	13,513	4.1 years	$	1.70
2025	$	1.32	15,015	4.1 years	$	1.32	15,015	4.1 years	$	1.32
2025	$	1.27	13,513	4.1 years	$	1.27	13,513	4.1 years	$	1.27
2025	$	1.41	34,000	4.2 years	$	1.41	34,000	4.1 years	$	1.41
2025	$	0.94	34,000	4.2 years	$	0.94	34,000	4.2 years	$	0.94
2025	$	1.17	120,000	4.2 years	$	1.17	120,000	4.2 years	$	1.17
2025	$	0.87	10,000	4.2 years	$	0.87	10,000	4.2 years	$	0.87
2025	$	0.81	10,000	4.3 years	$	0.81	10,000	4.3 years	$	0.81
2025	$	0.84	10,000	4.3 years	$	0.84	10,000	4.3 years	$	0.84


2025	$	0.81	10,000	4.3 years	$	0.81	10,000	4.3 years	$	0.81
2025	$	0.78	190,000	4.3 years	$	0.78	190,000	4.3 years	$	0.78
2025	$	0.59	50,000	4.3 years	$	0.59	50,000	4.3 years	$	0.59
2025	$	0.60	100,000	4.3 years	$	0.60	100,000	4.3 years	$	0.60
2025	$	0.58	100,000	4.4 years	$	0.58	100,000	4.4 years	$	0.58
2025	$	0.32	4,687,500	5.0 years	$	0.32	4,687,500	5.0 years	$	0.32
2025	$	0.40	187,500	4.4 years	$	0.40	187,500	4.4 years	$	0.40
2026	$	0.25	50,000	4.6 years	$	0.25	50,000	4.6 years	$	0.25
2026	$	0.19	50,000	4.6 years	$	0.19	50,000	4.6 years	$	0.19
2026	$	0.21	30,000	4.7 years	$	0.21	30,000	4.7 years	$	0.21
2026	$	0.12	83,623,126	1.4 years	$	0.12	83,623,126	1.4 years	$	0.12
2026	$	0.12	85,223,126	0	$	0.12	85,223,126	0	$	0.12
2026	$	0.0001	42,411,822	0	$	0.0001	42,411,822	0	$	0.0001
			219,470,313		$	0.16	219,470,313		$	0.16

The Series C Warrants will terminate 30 calendar days after the date the Company publicly announces data from its cosmetic filaggrin study in humans (subject to extension as described above), and the pre-funded warrants do not expire until exercised in full; accordingly, the remaining contractual life presented above for such warrants does not reflect a fixed expiration date.

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2026

Intangible Asset, Goodwill and Other [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following at:

June 30, 2026:


	Estimated Useful Life	Gross Amount		Accumulated Amortization		Impairment		Net Amount
Trademarks	Indefinite	$	60,244	$	—	$	—	$	60,244
Patents	17 years	319,788		49,993		—		269,795

Intangible assets		$	380,032	$	49,993	$	—	$	330,039

December 31, 2025:


	Estimated Useful Life	Gross Amount		Accumulated Amortization		Impairment		Net Amount
Trademarks	Indefinite	$	60,244	$	—	$	—	$	60,244
Patents	17 years	297,087		40,658		—		256,429

Intangible assets		$	357,331	$	40,658	$	—	$	316,673

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2026

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Payments Under Operating Leases

Future minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next five years follow:




2026	$	204,806
2027	194,145
2028	20,864
Thereafter	—
Total future undiscounted lease payments	419,815
Less interest	(11,248)
Present value of minimum lease payments	$	408,567

Schedule of Future Minimum Payments Under Finance Leases

The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, 2026.




2026	$	1,486


Total future undiscounted lease payments	1,486
Less interest	—
Present value of minimum lease payments	$	1,486

Stock Options - Schedule of Options Outstanding and Exercisable (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding (in shares)	651,871	139,922
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 8 months 12 days	9 years 8 months 12 days
Number of Options Exercisable (in shares)	53,242
Weighted Average Remaining Contractual Term, Vested and Exercisable	9 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 19.92
Exercise Price $0.21
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.21
Number of Options Outstanding (in shares)	514,684
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 9 months 18 days
Number of Options Exercisable (in shares)	0
Weighted Average Remaining Contractual Term, Vested and Exercisable	9 years 9 months 18 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0.21
Exercise Price $0.29
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.29
Number of Options Outstanding (in shares)	134,084
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 6 months
Number of Options Exercisable (in shares)	50,197
Weighted Average Remaining Contractual Term, Vested and Exercisable	9 years 6 months
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0.29
Exercise Price $340.20
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 340.20
Number of Options Outstanding (in shares)	2,903
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 8 months 12 days
Number of Options Exercisable (in shares)	2,903
Weighted Average Remaining Contractual Term, Vested and Exercisable	4 years 8 months 12 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 340.20
Exercise Price $413.59
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 413.59
Number of Options Outstanding (in shares)	200
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 2 months 12 days
Number of Options Exercisable (in shares)	142
Weighted Average Remaining Contractual Term, Vested and Exercisable	7 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 413.59

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Intangible Asset, Finite-Lived, before Accumulated Amortization [Abstract]
Accumulated Amortization	$ 49,993	$ 40,658
Impairment	0	0
Intangible Asset, Excluding Goodwill, after Accumulated Amortization [Abstract]
Gross Amount	380,032	357,331
Accumulated Amortization	49,993	40,658
Impairment	0	0
Net Amount	$ 330,039	$ 316,673
Patents
Intangible Asset, Finite-Lived, before Accumulated Amortization [Abstract]
Estimated Useful Life	17 years	17 years
Gross Amount	$ 319,788	$ 297,087
Accumulated Amortization	49,993	40,658
Impairment	0	0
Net Amount	269,795	256,429
Intangible Asset, Excluding Goodwill, after Accumulated Amortization [Abstract]
Accumulated Amortization	49,993	40,658
Impairment	0	0
Trademarks
Intangible Asset, Excluding Goodwill, Indefinite-Lived [Abstract]
Gross Amount	60,244	60,244
Impairment	0	0
Net Amount	$ 60,244	$ 60,244

Warrants - Schedule of Warrants Outstanding (Details) - $ / shares	6 Months Ended
	Jun. 30, 2026	Dec. 31, 2018
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)		$ 95.90
Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants outstanding (in shares)	219,470,313
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.16
Number of Warrants Exercisable (in shares)	219,470,313
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.16
2018 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 95.90
Number of warrants outstanding (in shares)	238
Warrants Outstanding, Weighted Average Remaining Contractual Life	1 year 9 months 18 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 95.90
Number of Warrants Exercisable (in shares)	238
Weighted Average Remaining Contractual Life, Warrants Exercisable	1 year 9 months 18 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 95.90
2023 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1,248.75
Number of warrants outstanding (in shares)	300
Warrants Outstanding, Weighted Average Remaining Contractual Life	2 years
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1,248.75
Number of Warrants Exercisable (in shares)	300
Weighted Average Remaining Contractual Life, Warrants Exercisable	2 years
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1,248.75
2024 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 75.92
Number of warrants outstanding (in shares)	3,336
Warrants Outstanding, Weighted Average Remaining Contractual Life	2 years 8 months 12 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 75.92
Number of Warrants Exercisable (in shares)	3,336
Weighted Average Remaining Contractual Life, Warrants Exercisable	2 years 8 months 12 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 75.92
2024 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 4.69
Number of warrants outstanding (in shares)	2,001,349
Warrants Outstanding, Weighted Average Remaining Contractual Life	3 years 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 4.69
Number of Warrants Exercisable (in shares)	2,001,349
Weighted Average Remaining Contractual Life, Warrants Exercisable	3 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 4.69
2024 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 12.49
Number of warrants outstanding (in shares)	40,030
Warrants Outstanding, Weighted Average Remaining Contractual Life	3 years 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 12.49
Number of Warrants Exercisable (in shares)	40,030
Weighted Average Remaining Contractual Life, Warrants Exercisable	3 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 12.49
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 2.50
Number of warrants outstanding (in shares)	29,175
Warrants Outstanding, Weighted Average Remaining Contractual Life	3 years 7 months 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 2.50
Number of Warrants Exercisable (in shares)	29,175
Weighted Average Remaining Contractual Life, Warrants Exercisable	3 years 7 months 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 2.50
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 3.60
Number of warrants outstanding (in shares)	337,232
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 3.60
Number of Warrants Exercisable (in shares)	337,232
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 3.60
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 2.33
Number of warrants outstanding (in shares)	11,216
Warrants Outstanding, Weighted Average Remaining Contractual Life	3 years 10 months 24 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 2.33
Number of Warrants Exercisable (in shares)	11,216
Weighted Average Remaining Contractual Life, Warrants Exercisable	3 years 10 months 24 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 2.33
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 2.17
Number of warrants outstanding (in shares)	11,261
Warrants Outstanding, Weighted Average Remaining Contractual Life	3 years 10 months 24 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 2.17
Number of Warrants Exercisable (in shares)	11,261
Weighted Average Remaining Contractual Life, Warrants Exercisable	3 years 10 months 24 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 2.17
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 2.12
Number of warrants outstanding (in shares)	11,261
Warrants Outstanding, Weighted Average Remaining Contractual Life	3 years 10 months 24 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 2.12
Number of Warrants Exercisable (in shares)	11,261
Weighted Average Remaining Contractual Life, Warrants Exercisable	3 years 10 months 24 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 2.12
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 2.32
Number of warrants outstanding (in shares)	11,261
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 2.32
Number of Warrants Exercisable (in shares)	11,261
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 2.32
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.86
Number of warrants outstanding (in shares)	13,513
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.86
Number of Warrants Exercisable (in shares)	13,513
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.86
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.78
Number of warrants outstanding (in shares)	13,513
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.78
Number of Warrants Exercisable (in shares)	13,513
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.78
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.75
Number of warrants outstanding (in shares)	13,513
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.75
Number of Warrants Exercisable (in shares)	13,513
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.75
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.70
Number of warrants outstanding (in shares)	13,513
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.70
Number of Warrants Exercisable (in shares)	13,513
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.70
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.32
Number of warrants outstanding (in shares)	15,015
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.32
Number of Warrants Exercisable (in shares)	15,015
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.32
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.27
Number of warrants outstanding (in shares)	13,513
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.27
Number of Warrants Exercisable (in shares)	13,513
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.27
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.41
Number of warrants outstanding (in shares)	34,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 2 months 12 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.41
Number of Warrants Exercisable (in shares)	34,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 1 month 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.41
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.94
Number of warrants outstanding (in shares)	34,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 2 months 12 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.94
Number of Warrants Exercisable (in shares)	34,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 2 months 12 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.94
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 1.17
Number of warrants outstanding (in shares)	120,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 2 months 12 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 1.17
Number of Warrants Exercisable (in shares)	120,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 2 months 12 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 1.17
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.87
Number of warrants outstanding (in shares)	10,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 2 months 12 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.87
Number of Warrants Exercisable (in shares)	10,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 2 months 12 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.87
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.81
Number of warrants outstanding (in shares)	10,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.81
Number of Warrants Exercisable (in shares)	10,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.81
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.84
Number of warrants outstanding (in shares)	10,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.84
Number of Warrants Exercisable (in shares)	10,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.84
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.81
Number of warrants outstanding (in shares)	10,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.81
Number of Warrants Exercisable (in shares)	10,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.81
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.78
Number of warrants outstanding (in shares)	190,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.78
Number of Warrants Exercisable (in shares)	190,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.78
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.59
Number of warrants outstanding (in shares)	50,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.59
Number of Warrants Exercisable (in shares)	50,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.59
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.60
Number of warrants outstanding (in shares)	100,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.60
Number of Warrants Exercisable (in shares)	100,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 3 months 18 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.60
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.58
Number of warrants outstanding (in shares)	100,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 4 months 24 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.58
Number of Warrants Exercisable (in shares)	100,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 4 months 24 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.58
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.32
Number of warrants outstanding (in shares)	4,687,500
Warrants Outstanding, Weighted Average Remaining Contractual Life	5 years
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.32
Number of Warrants Exercisable (in shares)	4,687,500
Weighted Average Remaining Contractual Life, Warrants Exercisable	5 years
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.32
2025 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.40
Number of warrants outstanding (in shares)	187,500
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 4 months 24 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.40
Number of Warrants Exercisable (in shares)	187,500
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 4 months 24 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.40
2026 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.25
Number of warrants outstanding (in shares)	50,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 7 months 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.25
Number of Warrants Exercisable (in shares)	50,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 7 months 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.25
2026 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.19
Number of warrants outstanding (in shares)	50,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 7 months 6 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.19
Number of Warrants Exercisable (in shares)	50,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 7 months 6 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.19
2026 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.21
Number of warrants outstanding (in shares)	30,000
Warrants Outstanding, Weighted Average Remaining Contractual Life	4 years 8 months 12 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.21
Number of Warrants Exercisable (in shares)	30,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	4 years 8 months 12 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.21
2026 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.12
Number of warrants outstanding (in shares)	83,623,126
Warrants Outstanding, Weighted Average Remaining Contractual Life	1 year 4 months 24 days
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.12
Number of Warrants Exercisable (in shares)	83,623,126
Weighted Average Remaining Contractual Life, Warrants Exercisable	1 year 4 months 24 days
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.12
2026 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.12
Number of warrants outstanding (in shares)	85,223,126
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.12
Number of Warrants Exercisable (in shares)	85,223,126
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.12
2026 \| Warrant
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 0.0001
Number of warrants outstanding (in shares)	42,411,822
Weighted Average Exercise Price, Warrants Outstanding (in dollars per share)	$ 0.0001
Number of Warrants Exercisable (in shares)	42,411,822
Weighted Average Exercise Price, Warrants Exercisable (in dollars per share)	$ 0.0001

Accrued Expenses (Details) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Payables and Accruals [Abstract]
Employee payroll and bonuses	$ 413,778	$ 29,528
Vacation	70,991	37,880
Research and development projects	28,346	84,408
Professional fees	159,065	45,527
Other	1,489	141
Total accrued expenses	$ 673,669	$ 197,484

Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
Intangible Assets - Narrative (Details) - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Intangible Asset, Goodwill and Other [Abstract]
Amortization of intangible assets	$ 4,724	$ 3,129	$ 9,335	$ 6,218

Summary of Significant Accounting Policies (Details)	1 Months Ended	3 Months Ended			6 Months Ended
Summary of Significant Accounting Policies (Details)	Sep. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Mar. 31, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) segment lease	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2023
Property, Plant, and Equipment [Line Items]
Number of operating segments \| segment					1
Deferred issuance costs written off	$ 35,435
Number of operating leases \| lease					3
Obtaining a right-of-use asset in exchange for lease liability					$ 1,418,502
Operating lease right-of-use asset, net		$ 406,455			406,455		$ 404,444
Current operating lease liability		357,569			357,569		255,776
Long-term operating lease liability		50,998			50,998		156,190
Lessee, finance lease, renewal term								36 months
Financing right-of-use assets, net value		1,301			1,301		9,041
Finance lease liability current		1,486			1,486		10,111
Long term finance lease liability		0			0
Impairment expenses		0	$ 623,532
Research and development		1,351,529		$ 1,401,839	2,912,094	$ 2,651,939
State tax credit receivable		103,601			103,601		103,601
Deferred tax assets, tax credit carryforwards, research		26,295			26,295		27,269
Deferred tax assets, tax credit carryforwards, other		$ 13,925			$ 13,925		$ 9,513
Minimum
Property, Plant, and Equipment [Line Items]
Lessee, operating lease, remaining lease term		36 months			36 months
Maximum
Property, Plant, and Equipment [Line Items]
Lessee, operating lease, remaining lease term		52 months			52 months

Stock Options - Narrative (Details)			1 Months Ended	6 Months Ended	12 Months Ended
Stock Options - Narrative (Details)	Jan. 01, 2026 shares	Oct. 03, 2024 shares	Mar. 31, 2023 shares	Jun. 30, 2026 USD ($) $ / shares shares	Dec. 31, 2025 $ / shares	Dec. 31, 2016 shares
Performance Shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized compensation expense \| $				$ 112,580
Options to purchase shares of common stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Underlying common stock value (in dollars per share) \| $ / shares				$ 0.21	$ 0.30
Expected volatility, minimum					86.70%
Expected volatility, maximum					89.10%
Risk free interest rate, minimum					3.86%
Risk free interest rate, maximum					4.12%
Dividend yield percentage				0.00%	0.00%
Expected volatility				86.70%
Risk free interest rate				4.12%
Options to purchase shares of common stock \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)				6 years 6 months	6 years 6 months
Options to purchase shares of common stock \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (years)				10 years	10 years
Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted (in shares)				514,684
2023 Stock Incentive Plan \| Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted (in shares)			181,842	648,968
Additional shares authorized (in shares)	537,034	171,832
Automatic increase, percentage of stock		0.05
Automatic increase, number of years		10 years
Stock options available for grants (in shares)				69,908
2016 Stock Incentive Plan \| Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted (in shares)				2,995		7,460
Stock options available for grants (in shares)				4,171

Commitments and Contingencies - Narrative (Details)	1 Months Ended				6 Months Ended		12 Months Ended
Commitments and Contingencies - Narrative (Details)	Apr. 30, 2026 USD ($)	Aug. 31, 2024 USD ($)	Sep. 30, 2021 USD ($)	May 31, 2021 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 CAD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CAD ($)	Jan. 26, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, term											10 years
License agreement, length of written notice required for termination					30 days
Rent expense for operating leases					$ 173,829	$ 164,205
Operating lease, weighted average remaining lease term					1 year 1 month 6 days
Operating lease, weighted average discount rate					4.91%
Finance lease monthly payments							$ 1,478
Finance lease term							3 years
Finance lease, remaining lease term							1 month 6 days
Finance lease, discount rate							9.60%
Finance lease expense					$ 7,740	7,740
Finance lease, interest expense					$ 243	$ 1,030
Montreal, Quebec
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease payments								$ 8,130		$ 6,906
Operating lease payments, percentage increase per year										0.04
Operating lease, initial lease term										1 year
Branford. CT
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease payments									$ 13,033
Operating lease payments, percentage increase per year					0.02
Groton. CT
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease payments	$ 9,716	$ 5,216	$ 6,824	$ 4,234
Operating lease, initial lease term				1 year
Operating lease, renewal term				3 years

Warrants - Narrative (Details)				1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
Warrants - Narrative (Details)	Mar. 20, 2026 USD ($) $ / shares shares	Aug. 24, 2024 USD ($) $ / shares	Jul. 25, 2024 USD ($) $ / shares yr shares	Aug. 31, 2024 USD ($) shares	Jun. 30, 2026 USD ($) shares	Mar. 31, 2026 shares	Jun. 30, 2026 USD ($) shares	Jun. 30, 2025 USD ($)	Dec. 31, 2018 $ / shares shares	Jun. 16, 2026 shares	Mar. 18, 2026 shares	Dec. 31, 2025 USD ($)	Nov. 24, 2025 $ / shares shares	Apr. 24, 2025	Feb. 28, 2025	Feb. 05, 2025 $ / shares shares	Jan. 14, 2025 $ / shares shares	Dec. 31, 2024	Jul. 31, 2024 $ / shares shares	Feb. 29, 2024 $ / shares shares	Feb. 16, 2024 $ / shares	Dec. 31, 2023 shares
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)									$ 95.90
Warrants outstanding, term									10 years
Sale of stock, price per share (in dollars per share)																				$ 60.74
Exercise of prefunded warrants (in shares) \| shares				150
Proceeds from exercise of warrants \| $				$ 704			$ 196,800	$ 0
Change in fair value of warrant liability \| $							0	$ (197)
Reclass of warrant liability \| $		$ 1,900,000
Measurement Input, Stay Public Assumption
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			0.90
Measurement Input, Transaction Assumption
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			0.10
Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			0
Measurement Input, Price Volatility
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			1.19
Measurement Input, Volume Weighted Average Price
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			1.14
Measurement Input, Expected Term
Class of Warrant or Right [Line Items]
Derivative liability, measurement input \| yr			4.92
Minimum \| Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			1.14
Minimum \| Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			0.0413
Minimum \| Measurement Input, Strike Price
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			1.40
Maximum \| Measurement Input, Share Price
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			1.40
Maximum \| Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			0.0414
Maximum \| Measurement Input, Strike Price
Class of Warrant or Right [Line Items]
Derivative liability, measurement input			1.50
Placement Agent Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)													$ 0.32						$ 12.49	$ 75.92
Warrants outstanding, term													5 years
Warrants issued (in shares) \| shares													187,500
Class of warrant or right, exercise term													6 months
Class A Warrant
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)			$ 9.99																$ 9.99
Warrants outstanding, term			5 years
Warrants issued (in shares) \| shares			2,001,502
Reset price (in dollars per share)		$ 4.69
Class of warrant or right, expiration term			5 years
Class of warrant or right, ownership limitation percentage			4.99%
Class of warrant or right, ownership limitation, election of the holder			9.99%
Warrant liability \| $			$ 12,100,000
Loss on issuance of common stock \| $			$ 2,100,000
Change in fair value of warrant liability \| $		$ 4,000,000.0
Follow-On Public Offering Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)																$ 3.60
The Warrants \| Alumni Capital
Class of Warrant or Right [Line Items]
Class of warrant or right, expiration term														5 years
Purchase agreement, warrants sold, as a percentage of shares sold														10.00%
Purchase agreement, warrant exercise price, percentage of price paid upon closing														130.00%
Pre-Funded Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)													$ 0.0001
Warrants issued (in shares) \| shares										48,507,897			4,151,741
Sale of stock, price per share (in dollars per share)													$ 0.32
Common Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)													$ 0.32
Warrants outstanding, term													5 years
Warrants issued (in shares) \| shares													4,687,500
Series B Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding, term										18 months
Series C Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding, term										30 days
Warrant price floor, percentage of original exercise price										50.00%
Underwriter
Class of Warrant or Right [Line Items]
Warrants outstanding, term																		5 years
Over-Allotment Option \| Underwriter
Class of Warrant or Right [Line Items]
Warrants issued (in shares) \| shares																			40,030	3,336		300
Follow-On Public Offering
Class of Warrant or Right [Line Items]
Sale of stock, price per share (in dollars per share)			$ 9.99													$ 1.85	$ 2.00				$ 59.94
Gross proceeds from follow-on public offering \| $			$ 10,000,000.0
Follow-On Public Offering \| Placement Agent Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)																	$ 2.50
Warrants issued (in shares) \| shares																	29,175
Class of warrant or right, expiration term																	5 years
Percentage of shares issued in transaction																	4.00%
Class of warrant or right, exercise price, percent of public offering price																	125.00%
Class of warrant or right, exercise term																	6 months
Follow-On Public Offering \| Follow-On Public Offering Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares) \| shares																337,232
Class of warrant or right, exercise term															6 months 1 day
Purchase Agreement \| Alumni Capital
Class of Warrant or Right [Line Items]
Gross proceeds from follow-on public offering \| $					$ 215,000		$ 215,000
Purchase Agreement \| ELOC Warrants, Issuance One \| Alumni Capital
Class of Warrant or Right [Line Items]
Number of warrants outstanding (in shares) \| shares					925,579		925,579
Private Placement
Class of Warrant or Right [Line Items]
Sale of stock, price per share (in dollars per share)													$ 0.32
Private Placement \| Placement Agent Warrants
Class of Warrant or Right [Line Items]
Percentage of shares issued in transaction													4.00%
Series A Offering
Class of Warrant or Right [Line Items]
Gross proceeds from follow-on public offering \| $	$ 10,400,000
Series A Offering \| Series A Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares) \| shares											85,223,126
Series A Offering \| Series B Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)	$ 0.123
Warrants issued (in shares) \| shares	85,223,126										85,223,126
Warrant term, upon stockholder approval										18 months
Series A Offering \| Series C Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)	$ 0.123
Warrants issued (in shares) \| shares	85,223,126
Warrant termination term, number of days after data announcement										30 days
Common Stock
Class of Warrant or Right [Line Items]
Convertible debt, warrants issued (in shares) \| shares									238
Exercise of prefunded warrants (in shares) \| shares					7,696,075	4,151,741
Warrant
Class of Warrant or Right [Line Items]
Fair value of warrants \| $					$ 0		$ 0					$ 0

Segment Information (Details)	6 Months Ended
Segment Information (Details)	Jun. 30, 2026 USD ($) segment
Segment Reporting [Line Items]
Number of reportable segments \| segment	1
UNITED STATES
Segment Reporting [Line Items]
Fixed assets, original cost basis	$ 942,051
Canada
Segment Reporting [Line Items]
Fixed assets, original cost basis	$ 294,564

Stock Options - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Options
Outstanding, beginning balance (in shares)	139,922
Exercised (in shares)	0
Forfeited (in shares)	(2,735)
Outstanding, ending balance (in shares)	651,871	139,922
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 12.10
Granted (in dollars per share)	0.21
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding, ending balance (in dollars per share)	$ 1.87	$ 12.10
Stock Options Additional Disclosures
Options Outstanding, Weighted Average Remaining Contractual Life	9 years 8 months 12 days	9 years 8 months 12 days
Weighted Average Remaining Contractual Term, Granted	9 years 9 months 18 days
Vested and Exercisable (in shares)	53,242
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 19.92
Weighted Average Remaining Contractual Term, Vested and Exercisable	9 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 0	$ 0
Aggregate Intrinsic Value, Vested and Exercisable	$ 0

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2026	Aug. 11, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	001-41705
Entity Registrant Name	Azitra, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4478536
Entity Address, Address Line One	21 Business Park Drive
Entity Address, City or Town	Branford
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06405
City Area Code	(203)
Local Phone Number	646-6446
Title of 12(b) Security	Common stock: Par value $0.0001
Trading Symbol	AZTR
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		60,603,742
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Amendment Flag	false
Entity Central Index Key	0001701478

Retirement Plan (Details)	6 Months Ended
Retirement Plan (Details)	Jun. 30, 2026 USD ($) hour	Jun. 30, 2025 USD ($)
Retirement Benefits [Abstract]
Consecutive months of service required	2 months
Minimum work hours	250
Minimum work hours in their first year of service	1,000
Percent of match on first three percent	100.00%
Employer matching contribution, percent of employees' gross pay	3.00%
Percent of match on next two percent	0.50
Employer matching contribution, additional percent of employees' gross pay	0.02
Employer matching contributions \| $	$ 9,000	$ 8,273

Concentration of Credit Risk	6 Months Ended
Concentration of Credit Risk	Jun. 30, 2026
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist principally of cash. The cash balance identified in the balance sheet is held in an account with a financial institution and insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. At times, cash maintained on deposit may be in excess of FDIC limits.

Net Loss Per Share (Details) - shares	6 Months Ended
Net Loss Per Share (Details) - shares	Jun. 30, 2026	Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	220,122,184	2,463,994
Options to purchase shares of common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	651,871	6,247
Warrants outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	219,470,313	2,457,747

Segment Information	6 Months Ended
Segment Information	Jun. 30, 2026
Segment Reporting [Abstract]
Segment Information	Segment Information The Company operates and manages its business as a single reportable segment, which is to discover and develop novel therapeutics to create a new paradigm for treating skin diseases. The Chief Executive Officer, who is the Chief Operating Decision Maker ("CODM"), manages and evaluates the Company's performance on a total Company basis of net loss and assessing how to allocate resources based on the Company cash position as reported in the Company's balance sheet and statement of operations. The Company's significant expenses are consistent with the expense categories presented in the statement of operations. As of June 30, 2026, all of the Company's fixed assets were maintained in the United States and Canada on an original costs basis of $942,051 and $294,564, respectively.

Organization and Nature of Operations (Details)											1 Months Ended	3 Months Ended		6 Months Ended		14 Months Ended	16 Months Ended
Organization and Nature of Operations (Details)	Jun. 16, 2026 shares	Mar. 20, 2026 USD ($) $ / shares shares	Nov. 24, 2025 $ / shares shares	Aug. 21, 2025	Feb. 05, 2025 USD ($) $ / shares shares	Jan. 14, 2025 USD ($) $ / shares shares	Jul. 25, 2024 USD ($) $ / shares shares	Jul. 01, 2024	Feb. 16, 2024 USD ($) $ / shares shares	May 17, 2023 $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2026 USD ($) $ / shares shares	Jun. 30, 2025 USD ($) shares	Jun. 30, 2026 USD ($) $ / shares shares	Jun. 30, 2025 USD ($) shares	Jun. 30, 2026 USD ($) $ / shares shares	Aug. 11, 2026 USD ($)	Mar. 31, 2026 USD ($)	Mar. 18, 2026 shares	Dec. 31, 2025 USD ($) $ / shares shares	Jul. 31, 2025 shares	Apr. 24, 2025 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jul. 31, 2024 $ / shares	Feb. 29, 2024 $ / shares	May 16, 2023 $ / shares	Dec. 31, 2018 $ / shares
Property, Plant, and Equipment [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares																										$ 60.74
Proceeds from initial public offering \| $														$ 0	$ 1,749,312
Stock split conversion ratio				0.1502				0.0333		7.1
Common stock, par value per share (in dollars per share) \| $ / shares										$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001				$ 0.0001							$ 0.01
Exercise price of warrants (in dollars per share) \| $ / shares																												$ 95.90
Common stock, shares authorized (in shares) \| shares										100,000,000		750,000,000	100,000,000	750,000,000	100,000,000	750,000,000				200,000,000	200,000,000
Warrants outstanding, term																												10 years
Stockholders' equity \| $												$ 7,334,339	$ 2,228,970	$ 7,334,339	$ 2,228,970	$ 7,334,339		$ 10,480,283		$ 3,801,230			$ 4,407,624	$ 5,698,298
Accumulated deficit \| $												75,796,096		75,796,096		75,796,096				68,521,196
Loss from operations \| $												$ 3,419,168	2,871,352	7,353,092	5,971,590
Net cash used in operating activities \| $														5,768,440	5,886,798
Working capital \| $														5,900,000
Common Stock
Property, Plant, and Equipment [Line Items]
Stock issued during conversion (in shares) \| shares	36,715,229											36,715,229
Stockholders' equity \| $												$ 6,060	$ 269	6,060	$ 269	$ 6,060		$ 1,619		$ 1,074			$ 224	$ 114
Alumni Capital
Property, Plant, and Equipment [Line Items]
Purchase agreement, maximum aggregate issuance value \| $																						$ 20,000,000
Class A Warrant
Property, Plant, and Equipment [Line Items]
Warrants issued (in shares) \| shares							2,001,502
Exercise price of warrants (in dollars per share) \| $ / shares							$ 9.99																		$ 9.99
Warrants outstanding, term							5 years
Follow-On Public Offering Warrants
Property, Plant, and Equipment [Line Items]
Exercise price of warrants (in dollars per share) \| $ / shares					$ 3.60
The Warrants \| Alumni Capital
Property, Plant, and Equipment [Line Items]
Purchase agreement, warrants sold, as a percentage of shares sold																						10.00%
Pre-Funded Warrants
Property, Plant, and Equipment [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares			$ 0.32
Warrants issued (in shares) \| shares	48,507,897		4,151,741
Exercise price of warrants (in dollars per share) \| $ / shares			$ 0.0001
Common Warrants
Property, Plant, and Equipment [Line Items]
Warrants issued (in shares) \| shares			4,687,500
Exercise price of warrants (in dollars per share) \| $ / shares			$ 0.32
Warrants outstanding, term			5 years
Series B Warrants
Property, Plant, and Equipment [Line Items]
Warrants outstanding, term	18 months
Series C Warrants
Property, Plant, and Equipment [Line Items]
Warrants outstanding, term	30 days
IPO
Property, Plant, and Equipment [Line Items]
Shares issued in connection with public offering and private placement (in shares) \| shares											7,508
Sale of stock, price per share (in dollars per share) \| $ / shares											$ 999.00
Proceeds from initial public offering \| $											$ 6,000,000.0
Follow-On Public Offering
Property, Plant, and Equipment [Line Items]
Shares issued in connection with public offering and private placement (in shares) \| shares					374,696	729,381	1,000,750		83,404
Sale of stock, price per share (in dollars per share) \| $ / shares					$ 1.85	$ 2.00	$ 9.99		$ 59.94
Net proceeds from follow-on public offering \| $					$ 560,976	$ 1,200,000	$ 9,100,000		$ 4,300,000
Gross proceeds from issuance of stock and warrants \| $							$ 10,000,000.0
Follow-On Public Offering \| Follow-On Public Offering Warrants
Property, Plant, and Equipment [Line Items]
Warrants issued (in shares) \| shares					337,232
Purchase Agreement \| Alumni Capital
Property, Plant, and Equipment [Line Items]
Shares issued in connection with public offering and private placement (in shares) \| shares																9,255,823
Gross proceeds from issuance of stock and warrants \| $												$ 215,000		$ 215,000
Purchase Agreement \| Alumni Capital \| Subsequent Event
Property, Plant, and Equipment [Line Items]
Gross proceeds from issuance of stock and warrants \| $																	$ 6,200,000
Value of shares available for future issuance \| $																	$ 13,800,000
Purchase Agreement \| ELOC Warrants, Issuance One \| Alumni Capital
Property, Plant, and Equipment [Line Items]
Number of warrants outstanding (in shares) \| shares												925,579		925,579		925,579
Private Placement
Property, Plant, and Equipment [Line Items]
Shares issued in connection with public offering and private placement (in shares) \| shares			535,759
Sale of stock, price per share (in dollars per share) \| $ / shares			$ 0.32
Series A Offering
Property, Plant, and Equipment [Line Items]
Shares issued in connection with public offering and private placement (in shares) \| shares	36,715,229
Net proceeds from follow-on public offering \| $		$ 10,400,000
Gross proceeds from issuance of stock and warrants \| $		$ 10,400,000
Number of units issued in transaction (in shares) \| shares		10,485
Convertible preferred stock, shares issuable (in shares) \| shares		85,223,126
Series A Offering \| Series A Preferred Stock
Property, Plant, and Equipment [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares		$ 1,000
Series A Offering \| Series B Warrants
Property, Plant, and Equipment [Line Items]
Warrants issued (in shares) \| shares		85,223,126																	85,223,126
Exercise price of warrants (in dollars per share) \| $ / shares		$ 0.123
Series A Offering \| Series C Warrants
Property, Plant, and Equipment [Line Items]
Warrants issued (in shares) \| shares		85,223,126
Exercise price of warrants (in dollars per share) \| $ / shares		$ 0.123

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 6,727,810	$ 2,068,083
Accounts receivable	909	912
Tax credits receivable	143,821	140,383
Prepaid expenses	571,282	809,949
Total current assets	7,443,822	3,019,327
Property and equipment, net	536,422	548,591
Financing lease right-of-use asset, net	1,301	9,041
Operating lease right-of-use asset, net	406,455	404,444
Intangible assets, net	330,039	316,673
Deferred patent costs	150,965	679,908
Other assets	47,042	47,402
Total assets	8,916,046	5,025,386
Current liabilities:
Accounts payable	497,985	399,356
Income tax payable	0	6,256
Current financing lease liability	1,486	10,111
Current operating lease liability	357,569	255,776
Insurance premium financing liability	0	198,983
Accrued expenses	673,669	197,484
Total current liabilities	1,530,709	1,067,966
Long-term operating lease liability	50,998	156,190
Total liabilities	1,581,707	1,224,156
Commitments and contingencies (Note 10)
Stockholders' equity
Preferred stock; $0.0001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025; respectively.	0	0
Common stock; $0.0001 par value, 750,000,000 and 200,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively, 60,603,742 and 10,740,697 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively.	6,060	1,074
Additional paid-in capital	83,124,375	72,321,352
Accumulated deficit	(75,796,096)	(68,521,196)
Total stockholders' equity	7,334,339	3,801,230
Total liabilities and stockholders' equity	$ 8,916,046	$ 5,025,386

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
General and administrative	$ 2,067,639	$ 1,469,513	$ 4,440,998	$ 3,319,651
Research and development	1,351,529	1,401,839	2,912,094	2,651,939
Total operating expenses	3,419,168	2,871,352	7,353,092	5,971,590
Loss from operations	(3,419,168)	(2,871,352)	(7,353,092)	(5,971,590)
Other income (expense):
Interest income	74,661	15,461	89,380	52,625
Interest expense	(1,365)	(468)	(4,776)	(1,761)
Change in fair value of warrants	0	54	0	197
Other expense	(1,788)	(32,688)	(6,412)	(36,809)
Total other income (expense)	71,508	(17,641)	78,192	14,252
Loss before income taxes	(3,347,660)	(2,888,993)	(7,274,900)	(5,957,338)
Income tax expense	0	0	0	0
Net loss attributable to common shareholders	$ (3,347,660)	$ (2,888,993)	$ (7,274,900)	$ (5,957,338)
Net loss per share, basic (in dollars per share)	$ (0.17)	$ (1.18)	$ (0.42)	$ (2.69)
Net loss per share, diluted (in dollars per share)	$ (0.17)	$ (1.18)	$ (0.42)	$ (2.69)
Weighted average common stock outstanding, basic (in shares)	19,300,704	2,444,340	17,419,798	2,212,293
Weighted average common stock outstanding, diluted (in shares)	19,300,704	2,444,340	17,419,798	2,212,293

Stockholders’ Equity	6 Months Ended
Stockholders’ Equity	Jun. 30, 2026
Equity [Abstract]
Stockholders’ Equity	Stockholders’ Equity On May 17, 2023, the Company effected a 7.1-for-1 Forward Stock Split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s preferred stock. The par value of the common stock was adjusted as a result of the Forward Stock Split from $0.01 to $0.0001 and the authorized shares were increased to 100,000,000 shares of common stock in connection with the Forward Stock Split. In lieu of any fractional shares issued as a result of the split the Company paid a cash amount to the holder of such fractional share. The accompanying financial statements and notes to the financial statements give retroactive effect to the Forward Stock Split for all periods presented. Shares of common stock underlying outstanding stock-based awards and other equity instruments were proportionately increased and the respective per share value and exercise prices, if applicable, were proportionately decreased in accordance with the terms of the agreements governing such securities. On February 16, 2024, the Company completed the February 2024 Offering, consisting of an aggregate of 83,404 shares of its common stock at a public offering price of $59.94 per share. The gross proceeds from the February 2024 Offering, before deducting the placement agent's fees and other offering expenses, were approximately $5 million. As consideration for ThinkEquity LLC serving as the Placement Agent for the February 2024 Offering (the "February 2024 Placement Agent"), the Company paid the February 2024 Placement Agent a cash fee of 7.5% of the aggregate gross proceeds of the February 2024 Offering and reimbursed the February 2024 Placement Agent for certain expenses, legal fees for a total of $537,559, and issued February 2024 Placement Agent Warrants to designees to the February 2024 Placement Agent. On July 1, 2024, the Company effected a 30-for-1 Reverse Stock Split of its issued and outstanding shares of common stock and began trading on a split-adjusted basis the same day. There was no change to the par value of the common stock. In lieu of any fractional shares issued as a result of the split the Company paid a cash amount to the holder of such fractional share. The accompanying financial statements and notes to the financial statements give retroactive effect to the Reverse Stock Split for all periods presented unless otherwise noted. Shares of common stock underlying outstanding stock-based awards and other equity instruments were proportionately decreased and the respective per share value and exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. On July 25, 2024, the Company completed the July 2024 Offering, consisting of an aggregate of 1,000,750 shares of its common stock and Class A warrants to purchase 2,001,502 shares of common stock, at a combined public offering price of $9.99. The Class A warrant had an initial exercise price of $9.99 per share, was exercisable immediately upon issuance, and will expire on the fifth anniversary of the original issuance date. However, if on the date that was 30 calendar days immediately following the date of issuance of the Class A Warrants, or August 24, 2024 (the “Reset Date”), the Reset Price, as defined below, was less than the exercise price at such time, the exercise price would be decreased to the Reset Price. “Reset Price” is defined as 100% of the trailing five-day VWAP immediately preceding the Reset Date, provided, that in no event would the Reset Price be less than $2.13 (subject to adjustment for reverse and forward stock splits, recapitalizations and similar transactions), which represented 20% of the most recent closing price for the Common Stock at the time of execution of the placement agent agreement with respect to the offering. The Reset Price of the Class A Warrants as calculated on the Reset Date was $4.69. The number of shares of Common Stock issuable upon exercise of the Class A Warrants has not been proportionately adjusted due to the reset of the exercise price. In consideration for Maxim Group LLC serving as the placement agent of the July 2024 Offering (the “July 2024 Placement Agent”), the Company paid the July 2024 Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds of the July 2024 Offering, reimbursed the July 2024 Placement Agent for certain expenses and legal fees for a total of $809,825, and issued Placement Agent Warrants. The gross proceeds from the July 2024 Offering, before deducting the July 2024 Placement Agent’s fees and other offering expenses, were approximately $10.0 million. On January 14, 2025, the Company completed the January 2025 Offering in which it issued and sold 729,381 shares of its common stock at a price of $2.00 per share. The net proceeds received by the Company from the January 2025 Offering were approximately $1.2 million, after deducting underwriting discounts, commissions and other offering expenses. The shares were offered by the Company pursuant to a shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and a final prospectus supplement dated January 15, 2025. In consideration for Maxim Group LLC serving as the placement agent of the January 2025 Offering (the "January 2025 Placement Agent"), the Company paid the January 2025 Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds raised in the January 2025 Offering and reimbursed the January 2025 Placement Agent for certain expenses and legal fees of $60,000. The Company also issued warrants to designees of the January 2025 Placement Agent (the "Placement Agent Warrants"). On February 5, 2025, the Company completed the February 2025 Offering in which it issued 374,696 shares of its common stock at a public offering price of $1.85 per share and warrants to purchase up to 337,232 shares of common stock. The net proceeds received by the Company from the February 2025 Offering were $561,000 after deducting placement agent's fees and other offering expenses. The shares were offered by the Company pursuant to a shelf registration statement on Form S-3 filed with the SEC on July 1, 2024, and a final prospectus supplement dated February 6, 2025. In consideration for Maxim Group LLC serving as the placement agent of the February 2025 Offering (the "February 2025 Placement Agent"), the Company paid the February 2025 Placement Agent a cash fee equal to 4.0% of the aggregate gross proceeds raised in the February 2025 Offering, reimbursed the February 2025 Placement Agent for certain expenses and legal fees of $35,000, and issued Placement Agent Warrants. On April 24, 2025, the Company entered into an ELOC, as amended, with Alumni Capital, whereby the Company has the right, but not the obligation, to sell to Alumni Capital, and Alumni Capital is obligated to purchase, up to an aggregate of $20 million of shares of the Company’s common stock in a series of purchases. The term of the ELOC is through December 31, 2026, or the date on which Alumni Capital shall have purchased the shares pursuant to the ELOC for an aggregate purchase price of $20 million. During the term, the Company may at its election cause Alumni Capital to make a series of purchases of shares, each up to $750,000, or up to $4 million dollars upon consent of Alumni Capital. The closing of each purchase pursuant to the ELOC will be no later than five business days after the Company provides a notice to Alumni Capital. The purchase price of the shares that the Company elects to sell to Alumni Capital pursuant to the ELOC will be equal to the lowest daily volume weighted average price of the Common Stock during the period commencing on the date that the Company delivers a notice requiring the purchase of shares by Alumni Capital and ending on the earlier to occur of (i) five (5) business days immediately following such date and (ii) the date on which Alumni Capital notifies the Company that it is prepared to proceed with the relevant closing, multiplied by 90%. On August 26, 2025, the Company entered into a Modification Agreement (the “Modification Agreement”) with Alumni Capital to amend certain terms of the Purchase Agreement, dated April 24, 2025, between the Company and Alumni Capital (the “Purchase Agreement”). Pursuant to the Modification Agreement, the Company may at its election, cause Alumni Capital to make a series of purchases of ELOC Shares either at (i) the lowest daily volume weighted average price of the Common Stock during the period commencing on the date that the Company delivers written notice (the “Purchase Notice”) and ending on the earlier of (a) five (5) business days immediately following the date of a Purchase Notice, and (b) the date on which Alumni Capital notifies the Company that it is prepared to proceed with the closing of the purchase, multiplied by 90% (“Purchase Notice Option 1”) or (ii) the lowest traded price of Common Stock during the period commencing on the date the Company delivers a Purchase Notice and ending on the earlier of (x) the same business day a Purchase Notice is delivered, and (y) the date on which Alumni Capital notifies the Company that it is prepared to proceed with the closing of the purchase, multiplied by 97% (“Purchase Notice Option 2”). Each Purchase Notice delivered by the Company must specify whether Purchase Notice Option 1 or Purchase Notice Option 2 is selected and the number of ELOC Shares to be purchased. All other terms and conditions of the Purchase Agreement remain in full force and effect. Refer to Note 7 regarding the terms of the warrants issued in conjunction with the shares. Through June 30, 2026 the Company has issued an aggregate 9,255,823 shares of common stock and issued an aggregate 925,579 warrants. During the three and six months ended June 30, 2026, the Company issued 1,300,000 shares of common stock and 130,000 warrants under the ELOC resulting in net proceeds of approximately $215,000. As of the date of this filing, the aggregate gross proceeds received by the Company under the ELOC were approximately $6.2 million. On November 24, 2025, the Company completed the November PIPE Offering of 535,759 shares of common stock of the Company, November Pre-Funded Warrants to purchase up to an aggregate of 4,151,741 shares of common at an exercise price of $0.0001 per November Pre-Funded Warrant, and November Common Warrants to purchase up to an aggregate of 4,687,500 shares of common stock at an exercise price of $0.32 per November Common Warrant. The offering price was $0.32 per share of common stock or November Pre-Funded Warrant and accompanying November Common Warrant Price. The November Pre-Funded Warrants are immediately exercisable and do not expire until exercised in full. The November Common Warrants are exercisable upon shareholder approval and will expire on the five-year anniversary of shareholder approval. For the three and six months ended June 30, 2026, all November Pre-Funded Warrants have been exercised by Alumni Capital. In consideration for Maxim Group LLC serving as the placement agent for the November PIPE Offering (the "PIPE Placement Agent"), the Company paid a cash fee equal to 7.0% of the aggregate gross proceeds raised in the November PIPE Offering, reimbursed the PIPE Placement Agent for certain expenses and legal fees of $50,000, and issued Placement Agent Warrants. On March 20, 2026, the Company completed the Series A Offering, for the sale of a unit, each unit consisting of one Series A Preferred Share ("Series A PS"), which is convertible into 8,128.1 shares of common stock, one Series B Warrant ("B Warrant") exercisable for 8,128.1 shares of common stock and one Series C Warrant ("C Warrant") exercisable for 8,128.1 shares of common stock (the "B Warrant and C Warrant" collectively the "Series A Preferred Warrants") and (the "Series A PS, B Warrant and C Warrant", collectively, the "Series A Unit") The Series A Preferred Warrants are exercisable at $0.123 per share of Common Stock under the Series A Preferred Warrants. The offering price was $1,000 per Series A Unit and a total of 10,485 Series A Units were sold in the Series A Offering resulting in net proceeds of approximately $10.4 million after deducting offering costs of approximately $101,000. Purchasers in the Series A Offering included the Company’s Chief Executive Officer, a consultant to the Company and a holder of more than 5% of the Company’s outstanding common stock as of the date of the Series A Purchase Agreement. On June 16, 2026 the Series A PS converted into 36,715,229 shares of common stock and 48,507,897 pre-funded warrants. The Series B Warrants became exercisable upon the requisite stockholder approval and will terminate 18 months following such approval. The Series C Warrants became exercisable upon the requisite stockholder approval and will terminate 30 calendar days after the date the Company publicly announces data from its cosmetic filaggrin study in humans; provided, however, that if the closing sale price of the common stock is below the exercise price of the Series C Warrants on such termination date, the exercise price will automatically reset to such closing sale price (subject to a floor equal to 50% of the original exercise price) and the termination date will be extended by an additional 30 calendar days. In June 2026, the Company filed a certificate of amendment to the Second Amended and Restated Certificate of Incorporation increasing the number of authorized shares of common stock from 200,000,000 to 750,000,000. There was no change in the common stock par value. Common Stock At June 30, 2026 and December 31, 2025, per the Company’s amended and restated Certificate of Incorporation, the Company was authorized to issue 750,000,000 and 200,000,000 shares of $0.0001 par value common stock, respectively. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Upon receiving stockholder approval of the Certificate of Amendment to the Amended and Restated Certificate of Incorporation, increasing the authorized number of shares of common stock from 200,000,000 to 750,000,000 shares at the 2026 Annual Meeting of Stockholders held on June 15, 2026, the Company reserved 220,122,184 shares of common stock for the potential exercise of stock options and warrants outstanding at June 30, 2026. As previously disclosed, the Company issued 36,715,229 shares of common stock upon the receipt of stockholder approval. Except as otherwise indicated, all share and share price amounts in this report give effect to a forward stock split effected on May 17, 2023 at a ratio of 7.1-for-1, a reverse stock split effected on July 1, 2024 at a ratio of 1-for-30, and a reverse stock split effected on August 21, 2025 at a ratio of 1-for-6.66. Preferred Stock At June 30, 2026 and December 31, 2025, per the Company’s Amended and Restated Certificate of Incorporation, the Company has authorized 10,000,000 shares of $0.0001 par value preferred stock. Upon receiving stockholder approval of the Certificate of Amendment to the Amended and Restated Certificate of Incorporation in June 2026, the 10,485 shares of Series A Preferred stock converted to 36,715,229 shares of common stock and 48,507,897 pre-funded warrants. No gain or loss was recorded upon conversion. Prior to conversion, the Series A Preferred were evaluated pursuant to ASC 480 - Distinguishing Liabilities from Equity and determined to be equity instruments.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Stockholders’ Equity (Details)											3 Months Ended			6 Months Ended		14 Months Ended	16 Months Ended
Stockholders’ Equity (Details)	Jun. 16, 2026 shares	Mar. 20, 2026 USD ($) $ / shares shares	Nov. 24, 2025 USD ($) $ / shares shares	Aug. 21, 2025	Feb. 05, 2025 USD ($) $ / shares shares	Jan. 14, 2025 USD ($) $ / shares shares	Jul. 25, 2024 USD ($) $ / shares shares	Jul. 01, 2024	Feb. 16, 2024 USD ($) $ / shares shares	May 17, 2023 $ / shares shares	Jun. 30, 2026 USD ($) $ / shares shares	Mar. 31, 2026 USD ($) shares	Jun. 30, 2025 USD ($) shares	Jun. 30, 2026 USD ($) vote $ / shares shares	Jun. 30, 2025 USD ($) shares	Jun. 30, 2026 $ / shares shares	Aug. 11, 2026 USD ($)	Jun. 15, 2026 shares	Mar. 18, 2026 shares	Dec. 31, 2025 $ / shares shares	Aug. 26, 2025	Jul. 31, 2025 shares	Apr. 24, 2025 USD ($)	Aug. 24, 2024 $ / shares	Jul. 31, 2024 $ / shares	Feb. 29, 2024 $ / shares	May 16, 2023 $ / shares	Dec. 31, 2018 $ / shares
Class of Stock [Line Items]
Stock split conversion ratio				0.1502				0.0333		7.1
Common stock, par value per share (in dollars per share) \| $ / shares										$ 0.0001	$ 0.0001			$ 0.0001		$ 0.0001				$ 0.0001							$ 0.01
Common stock, shares authorized (in shares)										100,000,000	750,000,000		100,000,000	750,000,000	100,000,000	750,000,000				200,000,000		200,000,000
Sale of stock, price per share (in dollars per share) \| $ / shares																										$ 60.74
Proceeds from follow-on public offering \| $														$ 215,950	$ 694,308
Placement agent fee, percentage of gross offering proceeds							0.070		0.075
Placement agent fee \| $							$ 809,825		$ 537,559
Exercise price of warrants (in dollars per share) \| $ / shares																												$ 95.90
Stock issuance costs \| $												$ 0	$ 79,985
Warrants outstanding, term																												10 years
Common stockholders, number of votes \| vote														1
Common stock, projected shares authorized (in shares)																		750,000,000
Common stock reserved for future issuance (in shares)																		220,122,184
Preferred stock, shares authorized (in shares)											10,000,000			10,000,000		10,000,000				10,000,000
Preferred stock, par value (in dollars per share) \| $ / shares											$ 0.0001			$ 0.0001		$ 0.0001				$ 0.0001
Preferred stock, shares outstanding (in shares)											0			0		0				0
Common Stock
Class of Stock [Line Items]
Stock issued during period (in shares)											1,300,000	1,300,000		1,300,000
Alumni Capital
Class of Stock [Line Items]
Purchase agreement, maximum aggregate issuance value \| $																							$ 20,000,000
Purchase agreement, series purchase limit \| $																							750,000
Purchase agreement, aggregate purchase limit \| $																							$ 4,000,000
Purchase agreement, closing period																					5 days		5 days
Purchase agreement, share price, volume weighted average price, number of days																							5 days
Purchase agreement, share price, volume weighted average price multiplier																							90.00%
Purchase agreement, share price, volume weighted average price multiplier, purchase notice option one																					90.00%
Purchase agreement, share price, volume weighted average price multiplier, purchase notice option two																					97.00%
Class A Warrant
Class of Stock [Line Items]
Warrants issued (in shares)							2,001,502
Exercise price of warrants (in dollars per share) \| $ / shares							$ 9.99																		$ 9.99
Reset price, number of days following issuance							30 days
Warrant reset price, percentage of volume weighted average price							1
Class of warrant or right, volume weighted average price, number of trading days							5 days
Reset price, floor (in dollars per share) \| $ / shares							$ 2.13
Warrant reset price, floor, percentage of closing stock price							0.20
Reset price (in dollars per share) \| $ / shares																								$ 4.69
Warrants outstanding, term							5 years
Follow-On Public Offering Warrants
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share) \| $ / shares					$ 3.60
Pre-Funded Warrants
Class of Stock [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares			$ 0.32
Warrants issued (in shares)	48,507,897		4,151,741
Exercise price of warrants (in dollars per share) \| $ / shares			$ 0.0001
Common Warrants
Class of Stock [Line Items]
Warrants issued (in shares)			4,687,500
Exercise price of warrants (in dollars per share) \| $ / shares			$ 0.32
Warrants outstanding, term			5 years
Series B Warrants
Class of Stock [Line Items]
Warrants outstanding, term	18 months
Series C Warrants
Class of Stock [Line Items]
Warrants outstanding, term	30 days
Warrant price floor, percentage of original exercise price	50.00%
Follow-On Public Offering
Class of Stock [Line Items]
Shares issued in connection with public offering and private placement (in shares)					374,696	729,381	1,000,750		83,404
Sale of stock, price per share (in dollars per share) \| $ / shares					$ 1.85	$ 2.00	$ 9.99		$ 59.94
Proceeds from follow-on public offering \| $									$ 5,000,000
Placement agent fee, percentage of gross offering proceeds					0.040	0.070
Gross proceeds from follow-on public offering \| $							$ 10,000,000.0
Net proceeds from follow-on public offering \| $					$ 560,976	$ 1,200,000	$ 9,100,000		$ 4,300,000
Stock issuance costs \| $					$ 35,000	$ 60,000
Follow-On Public Offering \| Follow-On Public Offering Warrants
Class of Stock [Line Items]
Warrants issued (in shares)					337,232
Purchase Agreement \| Alumni Capital
Class of Stock [Line Items]
Shares issued in connection with public offering and private placement (in shares)																9,255,823
Gross proceeds from follow-on public offering \| $											$ 215,000			$ 215,000
Purchase Agreement \| Alumni Capital \| Subsequent Event
Class of Stock [Line Items]
Gross proceeds from follow-on public offering \| $																	$ 6,200,000
Purchase Agreement \| ELOC Warrants, Issuance One \| Alumni Capital
Class of Stock [Line Items]
Warrants outstanding (in shares)											925,579			925,579		925,579
Warrants issued during period (in shares)											130,000			130,000
Private Placement
Class of Stock [Line Items]
Shares issued in connection with public offering and private placement (in shares)			535,759
Sale of stock, price per share (in dollars per share) \| $ / shares			$ 0.32
Placement agent fee, percentage of gross offering proceeds			0.070
Stock issuance costs \| $			$ 50,000									$ 100,806
Series A Offering
Class of Stock [Line Items]
Shares issued in connection with public offering and private placement (in shares)	36,715,229
Gross proceeds from follow-on public offering \| $		$ 10,400,000
Net proceeds from follow-on public offering \| $		10,400,000
Stock issuance costs \| $		$ 101,000
Sale of stock, price per unit (in dollars per share) \| $ / shares		$ 1,000
Number of units issued in transaction (in shares)		10,485
Series A Offering \| Pre-Funded Warrants
Class of Stock [Line Items]
Warrants issued during period (in shares)	48,507,897
Series A Offering \| Series B Warrants
Class of Stock [Line Items]
Warrants issued (in shares)		85,223,126																	85,223,126
Exercise price of warrants (in dollars per share) \| $ / shares		$ 0.123
Units issued in transaction, equity instrument per unit (in units)		1
Number of securities called by each warrant or right (in shares)		8,128.1
Series A Offering \| Series C Warrants
Class of Stock [Line Items]
Warrants issued (in shares)		85,223,126
Exercise price of warrants (in dollars per share) \| $ / shares		$ 0.123
Units issued in transaction, equity instrument per unit (in units)		1
Number of securities called by each warrant or right (in shares)		8,128.1
Series A Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)											10,485			10,485		10,485
Series A Preferred Stock \| Series A Offering
Class of Stock [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares		$ 1,000
Units issued in transaction, equity instrument per unit (in units)		1
Convertible preferred stock, shares issued upon conversion (in shares)		8,128.1

Property and Equipment - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment - Narrative (Details) - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Property, Plant, and Equipment [Abstract]
Depreciation	$ 34,069	$ 31,109	$ 67,150	$ 62,076
Gain (loss) on disposal of property and equipment	$ 0	$ 0	$ 0	$ 1,175

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (7,274,900)	$ (5,957,338)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	76,485	68,293
Gain/Loss on lease modification	(1,752)	7,726
Amortization of right-of-use assets	153,730	159,746
Stock based compensation	17,554	46,433
Change in fair value of warrant liability	0	(197)
Gain on disposal of property and equipment	0	(1,175)
Impairment of intangible assets and deferred patent costs	623,532	0
Changes in operating assets and liabilities:
Accounts receivable	3	233
Prepaid expenses	238,667	(107,984)
Other assets	360	(468)
Tax credits receivable	(3,438)	23,256
Income tax payable	(6,256)	(11,572)
Accounts payable and accrued expenses	557,223	40,432
Operating lease liability	(149,648)	(154,183)
Net cash used in operating activities	(5,768,440)	(5,886,798)
Cash flows from investing activities:
Purchases of property and equipment	(54,981)	(11,601)
Proceeds from sale of property and equipment	0	3,153
Deferred patent costs	(99,699)	(49,525)
Net cash used in investing activities	(154,680)	(57,973)
Cash flows from financing activities
Principal payments on finance leases	(8,625)	(7,838)
Proceeds from public offerings, net	0	1,749,312
Proceeds from exercise of warrants	196,800	0
Proceeds from private placement, net	10,377,703	0
Proceeds from equity line of credit	215,950	694,308
Repayment of insurance premium financing liability	(198,983)	0
Net cash provided by financing activities	10,582,845	2,435,782
Net change in cash and cash equivalents	4,659,725	(3,508,989)
Cash and cash equivalents at beginning of period	2,068,083	4,554,719
Cash and cash equivalents at end of period	6,727,808	1,045,730
Supplemental Cash Flow Information [Abstract]
Obtaining a right-of-use asset in exchange for lease liability	$ 166,690	$ 0

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)	3 Months Ended
	Mar. 31, 2025 USD ($)
Follow-On Public Offering One
Statement [Line Items]
Stock issuance costs	$ 269,948
Follow-On Public Offering Two
Statement [Line Items]
Stock issuance costs	$ 133,076

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred Stock, shares Outstanding (in shares)	0	0
Common stock, par value per share (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	750,000,000	200,000,000
Common stock, shares issued (in shares)	60,603,742	10,740,697
Common stock, shares outstanding (in shares)	60,603,742	10,740,697

Retirement Plan	6 Months Ended
Retirement Plan	Jun. 30, 2026
Retirement Benefits [Abstract]
Retirement Plan	Retirement PlanEffective January 1, 2019, the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate, an employee must complete two consecutive months of service and work a minimum of two hundred fifty hours or work 1,000 hours in their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1, 2020, the 401(k) was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed. Total employer matching contributions were $9,000 and $8,273 for the periods ended June 30, 2026 and 2025, respectively.

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Total	Follow-On Public Offering One	Follow-On Public Offering Two	Private Placement	Preferred Stock	Preferred Stock Private Placement	Common Stock	Common Stock Follow-On Public Offering One	Common Stock Follow-On Public Offering Two	Additional Paid-in-Capital	Additional Paid-in-Capital Follow-On Public Offering One	Additional Paid-in-Capital Follow-On Public Offering Two	Additional Paid-in-Capital Private Placement	Accumulated Deficit
Preferred stock, beginning balance (in shares) at Dec. 31, 2024					0
Common stock, beginning balance (in shares) at Dec. 31, 2024							1,145,038
Beginning balance at Dec. 31, 2024	$ 5,698,298				$ 0		$ 114			$ 63,264,009				$ (57,565,825)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued during period (in shares)								729,381	374,696
Stock issued during period		$ 1,186,293	$ 560,976					$ 73	$ 37		$ 1,186,220	$ 560,939
Stock-based compensation	30,402									30,402
Net loss	(3,068,345)													(3,068,345)
Preferred stock, ending balance (in shares) at Mar. 31, 2025					0
Common stock, ending balance (in shares) at Mar. 31, 2025							2,249,115
Ending balance at Mar. 31, 2025	4,407,624				$ 0		$ 224			65,041,570				(60,634,170)
Preferred stock, beginning balance (in shares) at Dec. 31, 2024					0
Common stock, beginning balance (in shares) at Dec. 31, 2024							1,145,038
Beginning balance at Dec. 31, 2024	5,698,298				$ 0		$ 114			63,264,009				(57,565,825)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(5,957,338)
Preferred stock, ending balance (in shares) at Jun. 30, 2025					0
Common stock, ending balance (in shares) at Jun. 30, 2025							2,699,113
Ending balance at Jun. 30, 2025	2,228,970				$ 0		$ 269			65,751,864				(63,523,163)
Preferred stock, beginning balance (in shares) at Mar. 31, 2025					0
Common stock, beginning balance (in shares) at Mar. 31, 2025							2,249,115
Beginning balance at Mar. 31, 2025	4,407,624				$ 0		$ 224			65,041,570				(60,634,170)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued during period (in shares)									449,998
Stock issued during period	694,308								$ 45			$ 694,263
Stock-based compensation	16,031									16,031
Net loss	(2,888,993)													(2,888,993)
Preferred stock, ending balance (in shares) at Jun. 30, 2025					0
Common stock, ending balance (in shares) at Jun. 30, 2025							2,699,113
Ending balance at Jun. 30, 2025	$ 2,228,970				$ 0		$ 269			65,751,864				(63,523,163)
Preferred stock, beginning balance (in shares) at Dec. 31, 2025	0				0
Common stock, beginning balance (in shares) at Dec. 31, 2025	10,740,697						10,740,697
Beginning balance at Dec. 31, 2025	$ 3,801,230				$ 0		$ 1,074			72,321,351				(68,521,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued during period (in shares)						10,485	1,300,000
Stock issued during period	215,950			$ 10,384,194			$ 130			215,820			$ 10,384,194
Exercise of Warrants (in shares)							4,151,741
Exercise of Warrants	0						$ 415			(415)
Stock-based compensation	6,149									6,149
Net loss	(3,927,240)													(3,927,240)
Preferred stock, ending balance (in shares) at Mar. 31, 2026					10,485
Common stock, ending balance (in shares) at Mar. 31, 2026							16,192,438
Ending balance at Mar. 31, 2026	$ 10,480,283				$ 0		$ 1,619			82,927,099				(72,448,435)
Preferred stock, beginning balance (in shares) at Dec. 31, 2025	0				0
Common stock, beginning balance (in shares) at Dec. 31, 2025	10,740,697						10,740,697
Beginning balance at Dec. 31, 2025	$ 3,801,230				$ 0		$ 1,074			72,321,351				(68,521,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued during period (in shares)							1,300,000
Net loss	$ (7,274,900)
Preferred stock, ending balance (in shares) at Jun. 30, 2026	0				0
Common stock, ending balance (in shares) at Jun. 30, 2026	60,603,742						60,603,742
Ending balance at Jun. 30, 2026	$ 7,334,339				$ 0		$ 6,060			83,124,374				(75,796,095)
Preferred stock, beginning balance (in shares) at Mar. 31, 2026					10,485
Common stock, beginning balance (in shares) at Mar. 31, 2026							16,192,438
Beginning balance at Mar. 31, 2026	10,480,283				$ 0		$ 1,619			82,927,099				(72,448,435)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued during period (in shares)							1,300,000
Exercise of Warrants (in shares)							7,696,075
Exercise of Warrants	196,800						$ 770			196,030
Conversion of Preferred Stock to Common Stock (in shares)					(10,485)		36,715,229
Conversion of Preferred Stock to Common Stock	0						$ 3,672			(3,672)
Stock-based compensation	11,405									11,405
Offering costs and other miscellaneous adjustments	(6,489)									(6,489)
Net loss	$ (3,347,660)													(3,347,660)
Preferred stock, ending balance (in shares) at Jun. 30, 2026	0				0
Common stock, ending balance (in shares) at Jun. 30, 2026	60,603,742						60,603,742
Ending balance at Jun. 30, 2026	$ 7,334,339				$ 0		$ 6,060			$ 83,124,374				$ (75,796,095)

Property and Equipment - Schedule of Property And Equipment (Details) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Property, Plant, and Equipment [Line Items]
Total property and equipment	$ 1,236,616	$ 1,181,636
Less accumulated depreciation & amortization	(700,194)	(633,045)
Total property and equipment, net	536,422	548,591
Laboratory equipment
Property, Plant, and Equipment [Line Items]
Total property and equipment	1,137,053	1,086,860
Computers and office equipment
Property, Plant, and Equipment [Line Items]
Total property and equipment	30,825	30,825
Furniture and fixtures
Property, Plant, and Equipment [Line Items]
Total property and equipment	24,951	20,164
Leasehold improvements
Property, Plant, and Equipment [Line Items]
Total property and equipment	28,855	28,855
Building equipment
Property, Plant, and Equipment [Line Items]
Total property and equipment	$ 14,932	$ 14,932

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company has evaluated events subsequent to the balance sheet date through August 12, 2026, the date these financial statements are issued. Other than as disclosed elsewhere in these notes to the unaudited condensed financial statements, the Company has not identified any subsequent events requiring recognition or disclosure in these financial statements.